The information on this page is designed for healthcare professionals, such as GPs, hospitals doctors in areas where the BEST4 Trials are taking place, to provide information about the trials.
The BEST4 platform is an exciting research programme of work co-funded by the NIHR and Cancer Research UK. Its primary objective is to determine whether the capsule sponge device can be used for early detection oesophageal cancer, with the ultimate goal of reducing the number of deaths from this form of cancer. The BEST4 platform consists of two trials:
The Surveillance trial aims to evaluate the use of the capsule sponge test, along with additional lab biomarker tests, to stratify individuals according to their risk for dysplasia and cancer, thereby enabling tailored follow-up procedures and reducing the burden of endoscopies.
The Screening Trial aims to assess the potential use of the capsule sponge test as a screening test for individuals at increased risk of oesophageal adenocarcinoma (OAC) due to age and heartburn history, with the objective of detecting cases of Barrett’s Oesophagus and early cancer and assessing overall impact on mortality.
The University of Cambridge and Cambridge University Hospital NHS Trust are joint sponsors. The Cancer Research UK & Queen Mary University of London Cancer Prevention Trials Unit (CPTU) are responsible for delivering the research. Clinical operations will be overseen by the Early Cancer Institute at University of Cambridge.
All capsule sponge samples will be sent to Cyted Ltd laboratories for processing and analysis.
Copyright © 2024 BEST4TRIAL - All Rights Reserved.